[HTML][HTML] Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Background Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival
benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We …
benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We …
Current status and factors influencing surgical options for breast cancer in China: a Nationwide cross‐sectional survey of 110 hospitals
B Yang, G Ren, E Song, D Pan, J Zhang… - The …, 2020 - academic.oup.com
Background There are limited nationwide data regarding breast cancer surgery in China. The
Chinese Anti‐Cancer Association's Committee of Breast Cancer Society and the Chinese …
Chinese Anti‐Cancer Association's Committee of Breast Cancer Society and the Chinese …
[HTML][HTML] An assessment of prognostic immunity markers in breast cancer
B Yang, J Chou, Y Tao, D Wu, X Wu, X Li, Y Li… - NPJ Breast …, 2018 - nature.com
… Benlong Yang was also supported in part by a grant awarded by the Shanghai Science
and Technology Committee Yang Fan project (15YF1402300). Lisa A. Carey's grant for 9830 …
and Technology Committee Yang Fan project (15YF1402300). Lisa A. Carey's grant for 9830 …
[HTML][HTML] Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999− 2017
R Guo, J Si, J Xue, Y Su, M Mo, B Yang… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
Objective Breast cancer in young females was usually considered more aggressive and
requires aggressive therapy. We investigated whether early detection and improved treatments …
requires aggressive therapy. We investigated whether early detection and improved treatments …
[HTML][HTML] The prognoses of young women with breast cancer (≤ 35 years) with different surgical options: a propensity score matching retrospective cohort study
P Li, L Li, B Xiu, L Zhang, B Yang, Y Chi, J Xue… - Frontiers in …, 2022 - frontiersin.org
Background Compared with older patients, young women with breast cancer (YWBCs) have
a poorer prognosis and a higher risk of recurrence. Ages ≤35 years are independent risk …
a poorer prognosis and a higher risk of recurrence. Ages ≤35 years are independent risk …
[HTML][HTML] Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization
…, W Chi, L Li, R Guo, J Xue, B Yang… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Despite the success of HER2-targeted therapy in achieving prolonged survival
in approximately 50% of treated individuals, treatment resistance is still an important …
in approximately 50% of treated individuals, treatment resistance is still an important …
Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
Tumor-infiltrating PD-1 hi dysfunctional CD8 + T cells have been identified in several tumors
but largely unexplored in breast cancer (BC). Here we aimed to extensively explore PD-1 hi …
but largely unexplored in breast cancer (BC). Here we aimed to extensively explore PD-1 hi …
Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy
Y Chen, C Chen, B Yang, Q Xu, F Wu, F Liu, X Ye… - Cancer letters, 2011 - Elsevier
PURPOSE: Clinical data suggest that the estrogen receptor (ER) contributes to chemotherapeutic
responsiveness. However, ER status alone is not consistently predictive. In this study, …
responsiveness. However, ER status alone is not consistently predictive. In this study, …
A nomogram for predicting axillary pathologic complete response in hormone receptor–positive breast cancer with cytologically proven axillary lymph node …
R Guo, Y Su, J Si, J Xue, B Yang, Q Zhang, W Chi… - Cancer, 2020 - Wiley Online Library
Background The objective of this study was to determine an axillary pathologic complete
response (pCR) and its influencing factors in patients with hormone receptor (HR)–positive …
response (pCR) and its influencing factors in patients with hormone receptor (HR)–positive …
Predicting sentinel lymph node metastasis in a Chinese breast cancer population: assessment of an existing nomogram and a new predictive nomogram
…, B Yang, Z Liu, X Huang, G Liu, Q Han, W Yang… - Breast cancer research …, 2012 - Springer
We assessed the MSKCC nomogram performance in predicting SLN metastases in a
Chinese breast cancer population. A new model (the SCH nomogram) was developed with …
Chinese breast cancer population. A new model (the SCH nomogram) was developed with …
